Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Santen Pharmaceutical Co., Ltd.

SNPHYPNK
Healthcare
Drug Manufacturers - General
$11.12
$-0.36(-3.14%)
U.S. Market opens in 9h 45m

Santen Pharmaceutical Co., Ltd. (SNPHY) Stock Competitors & Peer Comparison

See (SNPHY) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
SNPHY$11.12+0.00%3.7B18.82$0.61+1.88%
BMYMP$1,002.93+0.29%2T4457.47$0.23+4.11%
RHHBF$483.97-0.62%385.2B23.21$20.85+2.27%
RHHBY$59.18+0.00%382B22.81$2.60+1.45%
RHHVF$477.44+0.00%366.2B22.06$20.85+2.39%
AZNCF$208.62-0.02%323.4B34.60$6.03+1.51%
NVSEF$166.34+3.00%317.4B23.23$7.16+2.39%
GLAXF$31.48+0.02%125.9B16.51$1.89+2.83%
SNYNF$93.97+0.00%115B19.84$4.79+4.64%
CHGCY$30.75+0.00%105.8B37.39$0.86+2.56%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

SNPHY vs BMYMP Comparison February 2026

SNPHY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNPHY stands at 3.7B. In comparison, BMYMP has a market cap of 2T. Regarding current trading prices, SNPHY is priced at $11.12, while BMYMP trades at $1,002.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNPHY currently has a P/E ratio of 18.82, whereas BMYMP's P/E ratio is 4457.47. In terms of profitability, SNPHY's ROE is +0.11%, compared to BMYMP's ROE of +0.39%. Regarding short-term risk, SNPHY is more volatile compared to BMYMP. This indicates potentially higher risk in terms of short-term price fluctuations for SNPHY.Check BMYMP's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions